GlassScriptPhysician profile
Keith C Charles
NPI 1255334389
$1,489.76
in general payments reported to CMS, 2019-2025
14 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $40.35 · 2021: $425 · 2022: $340 · 2023: $45.27 · 2024: $228 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $535.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $583.16 | 2019-2024 | Clareon |
| Dompe US, INC. | $548.09 | 2021-2025 | Oxervate |
| Abbvie INC. | $91.49 | 2025 | |
| Allergan, INC. | $40.77 | 2021 | |
| Shire North American Group INC | $40.26 | 2019 | |
| Horizon Therapeutics Plc | $39.55 | 2019 | |
| Astellas Pharma US INC | $28.01 | 2025 | Izervay |
| Johnson & Johnson Surgical Vision, INC. | $25.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.94 | 2023 | |
| Bausch & Lomb Americas INC. | $20.00 | 2025 | Miebo |
| Oyster Point Pharma, INC. | $18.14 | 2022 | |
| Mallinckrodt Hospital Products INC. | $16.59 | 2025 | Acthar |
| Apellis Pharmaceuticals, INC. | $15.92 | 2025 | Syfovre |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.